Moscow, Sept 7: Russia has developed Enteromix, the world’s first mRNA-based cancer vaccine, which has shown 100% efficacy and safety in clinical trials. The breakthrough has raised fresh hope for millions battling cancer worldwide.
The vaccine has already entered early clinical use at select oncology centers and now awaits final clearance from the Ministry of Health for mass rollout.
Built on the same mRNA technology used in COVID-19 vaccines, Enteromix is a next-generation therapy designed to train the immune system to precisely target and destroy cancer cells without harming healthy tissue. Unlike chemotherapy or radiation, no serious side effects were reported during trials.Click Here To Follow Our WhatsApp Channel
The vaccine, developed by the National Medical Research Radiological Centre in collaboration with the Engelhardt Institute of Molecular Biology (EIMB), is given through a simple intramuscular injection.
Experts say patients with lung, breast, colorectal, pancreatic cancers, hereditary cancer syndromes like BRCA1/2, chemotherapy-resistant tumors, and even immunocompromised individuals could benefit from the treatment.
With final approval pending, Enteromix is being hailed as a potential game-changer in global cancer care.(KNS)